- Home
- SSBK vs BNTC Comparison
SSBK vs BNTC Comparison
Compare SSBK & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- BNTC
- Stock Information
- Founded
- SSBK 2007
- BNTC 1995
- Country
- SSBK United States
- BNTC United States
- Employees
- SSBK N/A
- BNTC N/A
- Industry
- SSBK Commercial Banks
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- BNTC Health Care
- Exchange
- SSBK Nasdaq
- BNTC Nasdaq
- Market Cap
- SSBK 330.0M
- BNTC 339.8M
- IPO Year
- SSBK 2021
- BNTC N/A
- Fundamental
- Price
- SSBK $32.56
- BNTC $16.11
- Analyst Decision
- SSBK Buy
- BNTC Strong Buy
- Analyst Count
- SSBK 1
- BNTC 7
- Target Price
- SSBK $36.00
- BNTC $24.43
- AVG Volume (30 Days)
- SSBK 13.7K
- BNTC 37.6K
- Earning Date
- SSBK 04-21-2025
- BNTC 05-12-2025
- Dividend Yield
- SSBK 1.09%
- BNTC N/A
- EPS Growth
- SSBK 3.77
- BNTC N/A
- EPS
- SSBK 3.67
- BNTC N/A
- Revenue
- SSBK $94,140,000.00
- BNTC N/A
- Revenue This Year
- SSBK $19.13
- BNTC N/A
- Revenue Next Year
- SSBK $7.78
- BNTC N/A
- P/E Ratio
- SSBK $8.72
- BNTC N/A
- Revenue Growth
- SSBK 13.56
- BNTC N/A
- 52 Week Low
- SSBK $22.13
- BNTC $4.75
- 52 Week High
- SSBK $39.16
- BNTC $15.97
- Technical
- Relative Strength Index (RSI)
- SSBK 52.72
- BNTC 70.37
- Support Level
- SSBK $31.49
- BNTC $14.90
- Resistance Level
- SSBK $33.14
- BNTC $15.97
- Average True Range (ATR)
- SSBK 0.85
- BNTC 1.03
- MACD
- SSBK 0.15
- BNTC 0.32
- Stochastic Oscillator
- SSBK 74.34
- BNTC 85.59
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.